All Posts

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Jul 6, 2026

•

5 min read

Margin Call: The Optiscan Story (ASX: OIL)

Jul 2, 2026

•

12 min read

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

Jul 1, 2026

•

7 min read

A Closer Look at the ASX Supervision Report

Jun 30, 2026

•

6 min read

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jun 29, 2026

•

4 min read

Is Medtech Back?

Jun 26, 2026

•

3 min read

My Third Armchair Pick: Control Bionics (ASX: CBL)

Jun 25, 2026

•

13 min read

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Jun 24, 2026

•

4 min read

Fighting over the shrinking pie

Jun 23, 2026

•

9 min read

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Jun 22, 2026

•

9 min read

Tax On, Tax Off: What new changes mean for biotech

Jun 19, 2026

•

4 min read

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Jun 18, 2026

•

4 min read

...

All Posts

A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Margin Call: The Optiscan Story (ASX: OIL)

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

A Closer Look at the ASX Supervision Report

Acid Test: Definium’s Positive Phase 3 LSD Readout

Is Medtech Back?

My Third Armchair Pick: Control Bionics (ASX: CBL)

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Fighting over the shrinking pie

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Tax On, Tax Off: What new changes mean for biotech

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

The Armchair Analyst